Please login to the form below

Incivek

This page shows the latest Incivek news and features for those working in and with pharma, biotech and healthcare.

Access to new hep C treatments put under the spotlight

It can also be used in patients with advanced liver disease and who have failed prior treatment with HCV protease inhibitors such as Merck &Co's Victrelis (boceprevir) and Vertex' Incivek

Latest news

FDA approves four new medicines across multiple areas

and Vertex' Incivek (telaprevir).
J&J starts to feel biosimilar competition bite

its toll on J&J's Olysio (simeprevir) and Incivek (telaprevir) products.
Top biotech firms saw sales jump in 2014

Dion added: “ This drop was largely attributable to sliding sales of Incivek (telaprevir), Vertex's hepatitis C virus protease inhibitor, which fell by $442.3m compared with 2013, primarily as a
The end of hepatitis C?

The launch a few years ago of first-generation protease inhibitors to the pharmaco-therapeutic arsenal - Vertex' Incivek (telaprevir) and Merck &Co's Victrelis (boceprevir) - drastically improved success rates in some
BMS can ride on Sovaldi's success as Daklinza cleared in EU

patients with advanced liver disease and who have failed prior treatment with HCV protease inhibitors such as Merck &Co's Victrelis (boceprevir) and Vertex' Incivek (telaprevir).

More from news
Approximately 1 fully matching, plus 31 partially matching documents found.

Latest from PMHub

Warehousing of HCV patients reaches new high

New drugs from Vertex (Incivek) and Merck (Victrelis) have been welcomed because they are more effective, but they still need to be given with Interferon.

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

HOME BASED Senior Account Executive / Account Manager - Medical ...: Salary TBC

Senior / Principal Regulatory Writer – Home Working - UK or US: HIGHLEY COMPETATIVE SALARY, BONUS &BENEFITS

Head of Operations/ BUD, Healthcare PR, London – Excellent leade...: Excellent Package

Medical Writer - (London, Brighton or Copenhagen): Competitive

Senior Medical Writer: Great salary and benefits

Digital Senior Account Director – Healthcare Advertising – Londo...: Salary TBC

Editor > Senior Editor – Medical Education – London: Very competitive with excellent benefits

Account Manager – Med Comms – London: Salary TBC

Senior Account Manager or AD - Medical Communications: Salary TBC

Account Manager, Healthcare PR: £40, 000 – £42, 000 great benefits and bonuses

Engagement Strategist, Healthcare Brand Communications, London, ...: Circa £60K

Science writer, Healthcare Brand Communications, London, £45-50K...: £45-50K

Principal Medical Writer, Medical Communications, Relocate to Ca...: Excellent Salary

Account Director - Global Healthcare Advertising (Digital) - Lon...: £55000 - £65000

Editorial Team Leader or Scientific Director: £50, 000 - £55, 000 benefits

Senior Medical Writer: Great salary and bebefits

Scientific Director: Great salary and bebefits

FREELANCE Account Manager – Creative Healthcare Advertising – Lo...: SUPERB DAY RATES AVAILABLE

Senior Account Manager – Med Comms – Kent: Salary TBC

Senior Medical Writer, Medical Communications, Relocate to Cardi...: Excellent Salary

Senior Programme Executive: Salary TBC

Senior Account Manager / Account Director: Great salary and bebefits

FREELANCE OPPORTUNITIES!!!!! Medical Education - Healthcare Adve...: EXCELLENT DAY RATES AVAILABLE

Subscribe to our email news alerts

PMHub

Add my company

GCI Health

GCI Health London is a young, vibrant powerhouse in the European industry with a mission to redefine healthcare communications, starting...

Latest intelligence

No Voice, No Choice: Adelphi Research UK’s insights help to campaign for change in the Mental Health Act...
Pharma’s isolated islands of innovation: With service design and technology often failing the patient, why perspective on improving outcomes need to change...
Uncertainty, austerity and Brexit: What does it mean for the life science sector?...